GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
No safety concern was observed. The TH HSV REC-003 study will continue for routine safety monitoring and to generate follow-up.GSK Plc (NYSE:GSK) shelved on Wednesday its herpes simplex virus (HSV) vaccine development program.
葛蘭素史克公司（紐約證券交易所代碼：GSK）週三擱置了其單純皰疹病毒（HSV）疫苗開發計劃。
The recombinant protein vaccine, dubbed GSK3943104, did not meet the study's primary efficacy objective.
這種名爲 GSK3943104 的重組蛋白疫苗未達到該研究的主要療效目標。
GSK added that the vaccine candidate will not progress to phase three studies.
GsK補充說，候選疫苗不會進入第三階段的研究。
No safety concern was observed. The TH HSV REC-003 study will continue for routine safety monitoring and to generate follow-up.
未觀察到安全問題。TH HSV REC-003 研究將繼續進行常規安全監測並進行後續跟進。
"Given the unmet medical need and burden associated with genital herpes, innovation in this area is still needed," the company said. "GSK intends to evaluate the totality of all these data and other studies to progress future research and development of its HSV program."
該公司表示：「鑑於與生殖器皰疹相關的醫療需求和負擔未得到滿足，該領域仍需要創新。」「葛蘭素史克打算評估所有這些數據和其他研究的總體情況，以推進其HSV計劃的未來研發。」
There are no approved vaccines for HSV, and GSK's decision to stop developing GSK3943104 eliminates a key contender in the race to market.
目前尚無獲批准的單純皰疹病毒疫苗，葛蘭素史克決定停止開發 GSK3943104，這使市場競賽中的關鍵競爭者望而卻步。
Moderna Inc (NASDAQ:MRNA) is developing mRNA-1608, an investigational vaccine for herpes simplex virus type 2. The candidate is currently in phase 1/2 trial that is fully enrolled with 300 participants in the U.S. Data is expected in June 2025.
摩德納公司（納斯達克股票代碼：MRNA）正在開發mRNA-1608，這是一種針對2型單純皰疹病毒的研究性疫苗。該候選人目前正在進行1/2期試驗，該試驗已全部入組，美國有300名參與者。數據預計將於2025年6月公佈。
Pfizer Inc. (NYSE:PFE) partner BioNTech SE (NASDAQ:BNTX) is developing BNT163, a prophylactic vaccine candidate being studied in a phase one clinical trial.
輝瑞公司（紐約證券交易所代碼：PFE）合作伙伴BioNTech SE（納斯達克股票代碼：BNTX）正在開發 BNT163，這是一種正在第一階段臨床試驗中研究的預防性候選疫苗。
The German company initiated the phase one trial in December 2022, with an estimated enrollment of 248 participants. Data is expected in 2025.
這家德國公司於2022年12月啓動了第一階段試驗，估計註冊了248名參與者。數據預計將在2025年公佈。
There are an estimated four billion people globally infected with HSV.
據估計，全球有40億人感染了單純皰疹病毒。
GSK Price Action: GSK stock is down 1.12% at $43.61 at last check Wednesday.
葛蘭素史克價格走勢：在週三的最後一次檢查中，葛蘭素史克股價下跌1.12％，至43.61美元。
- Rocket Lab USA Hires Rivian Veteran Frank Klein As New COO – What's Going On?
- 美國火箭實驗室聘請 Rivian 資深人士弗蘭克·克萊因擔任新任首席運營官——發生了什麼？
